文献速递血液净化与透析肾血管病与高血压

雷米普利对维持性血液透析患者心血管结局的影响:ARCADIA多中心随机对照试验

Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-03-29

在血压控制相当的情况下,雷米普利未减少心血管死亡、心肌梗死或卒中的复合终点(HR 0.93,95%CI 0.52–1.64,P=0.80),但降低 1 年心脏质量指数,且低血压发作更常见。

要点

  • 雷米普利未降低维持性血透患者主要心血管复合终点风险(HR 0.93,P=0.80)。
  • 雷米普利组 1 年心脏质量指数较基线变化优于对照组(组间差 -16.3 g/m2)。
  • 雷米普利组低血压发作更频繁(41% vs 12%),需关注耐受性。

核心结论

  • 在维持性血液透析伴高血压和/或左心室肥厚患者中,雷米普利未降低主要心血管事件风险。
  • 雷米普利可降低 1 年心脏质量指数,但低血压发作更常见。

研究设计与样本

  • 3 期、前瞻性、随机、开放标签、盲法终点、平行、多中心试验,自意大利 28 个中心招募。
  • 2009 年 7 月至 2014 年 2 月随机分配 140 例至雷米普利(1.25–10 mg/d)、129 例至非 RAS 抑制治疗。
  • 两组均滴定至最大耐受剂量以达到预设目标血压,结局评估至随机后 42 个月。

主要发现

  • 雷米普利组 23 例(16%)、对照组 24 例(19%)达到主要复合终点(HR 0.93,95%CI 0.52–1.64,P=0.80)。
  • 雷米普利组 1 年心脏质量指数较基线变化与对照组组间差为 -16.3 g/m2(95%CI -29.4 至 -3.1)。
  • 雷米普利组低血压发作 41%、对照组 12%;雷米普利组 20 例、对照组 9 例发生癌症。
  • 雷米普利组 6 例胃肠道恶性肿瘤(4 例致命),对照组无胃肠道恶性肿瘤。

关键数值与推荐

  • 主要疗效终点为心血管死亡、心肌梗死或卒中的复合终点。
  • 雷米普利剂量范围 1.25–10 mg/d,滴定至最大耐受剂量以达到预设目标血压。

临床怎么用

  • 对维持性血透伴高血压和/或左心室肥厚患者,不应期望雷米普利显著减少主要心血管事件。
  • 使用雷米普利需监测低血压发作,并关注癌症发生风险信号。

局限性

  • 开放标签设计,仅终点评估设盲。
  • 癌症为探索性观察,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Renin-angiotensin system (RAS) inhibitors reduce cardiovascular morbidity and mortality in patients with CKD. We evaluated the cardioprotective effects of the angiotensin-converting enzyme inhibitor ramipril in patients on maintenance hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this phase 3, prospective, randomized, open-label, blinded end point, parallel, multicenter trial, we recruited patients on maintenance hemodialysis with hypertension and/or left ventricular hypertrophy from 28 Italian centers. Between July 2009 and February 2014, 140 participants were randomized to ramipril (1.25-10 mg/d) and 129 participants were allocated to non-RAS inhibition therapy, both titrated up to the maximally tolerated dose to achieve predefined target BP values. The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included the single components of the primary end point, new-onset or recurrence of atrial fibrillation, hospitalizations for symptomatic fluid overload, thrombosis or stenosis of the arteriovenous fistula, and changes in cardiac mass index. All outcomes were evaluated up to 42 months after randomization. RESULTS: At comparable BP control, 23 participants on ramipril (16%) and 24 on non-RAS inhibitor therapy (19%) reached the primary composite end point (hazard ratio, 0.93; 95% confidence interval, 0.52 to 1.64; P=0.80). Ramipril reduced cardiac mass index at 1 year of follow-up (between-group difference in change from baseline: -16.3 g/m2; 95% confidence interval, -29.4 to -3.1), but did not significantly affect the other secondary outcomes. Hypotensive episodes were more frequent in participants allocated to ramipril than controls (41% versus 12%). Twenty participants on ramipril and nine controls developed cancer, including six gastrointestinal malignancies on ramipril (four were fatal), compared with none in controls. CONCLUSIONS: Ramipril did not reduce the risk of major cardiovascular events in patients on maintenance hemodialysis. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ARCADIA, NCT00985322 and European Union Drug Regulating Authorities Clinical Trials Database number 2008-003529-17.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Ruggenenti P, Podestà MA, Trillini M, et al. Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial. Clin J Am Soc Nephrol. 2021. PMID: 33782036. doi:10.2215/CJN.12940820

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。